These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2369816)

  • 1. In vitro studies of ciprofloxacin and survey of resistance patterns in current isolates.
    Fernandes CJ; Ackerman VP
    Diagn Microbiol Infect Dis; 1990; 13(2):79-91. PubMed ID: 2369816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility of nosocomial Pseudomonas aeruginosa, enterobacteriaceae, and staphylococci to ciprofloxacin and ten other broad-spectrum antibiotics.
    Weinstein RA; Nathan C; Delzell D; Kabins SA
    Chemioterapia; 1987 Oct; 6(5):315-8. PubMed ID: 3123078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activity of the new fluoroquinolone BMY-40062.
    Chin NX; Neu H
    Eur J Clin Microbiol Infect Dis; 1990 Aug; 9(8):620-4. PubMed ID: 2120060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of PD 117596-2, a broad-spectrum difluoroquinolone.
    Neu HC; Chin NX
    Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):644-50. PubMed ID: 2506029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The sensitivity of gentamicin-resistant gram-negative bacilli to cefotaxime, other cephalosporins and aminoglycosides.
    Stephens M; Potten M; Bint AJ
    Infection; 1979; 7(3):109-12. PubMed ID: 478651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of A-56619 and A-56620 against multi-resistant and routine clinical isolates.
    Fernandes CJ; Wilson RD; Ackerman VP
    Chemotherapy; 1988; 34(3):216-28. PubMed ID: 3416660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
    Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
    Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The most frequent aminoglycoside resistance mechanisms--changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups.
    Miller GH; Sabatelli FJ; Hare RS; Glupczynski Y; Mackey P; Shlaes D; Shimizu K; Shaw KJ
    Clin Infect Dis; 1997 Jan; 24 Suppl 1():S46-62. PubMed ID: 8994779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity.
    Jones RN; Thornsberry C
    Rev Infect Dis; 1982; 4 Suppl():S300-15. PubMed ID: 6294779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparative in-vitro activity of pefloxacin.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():1-10. PubMed ID: 2940213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fleroxacin combined with rifampin.
    Zhang YX; Neu HC
    Diagn Microbiol Infect Dis; 1991; 14(1):23-7. PubMed ID: 1901534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of ciprofloxacin against gram-positive cocci.
    Barry AL; Jones RN
    Am J Med; 1987 Apr; 82(4A):27-32. PubMed ID: 3578323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activity of cefepime against nosocomial isolates.
    Sofianou D; Tsoulfa S; Kontodimou L; Polydorou F; Malaka E
    J Chemother; 1997 Oct; 9(5):341-6. PubMed ID: 9373789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.
    Jones RN; Barrett MS; Erwin ME; Briggs BM; Johnson DM
    Diagn Microbiol Infect Dis; 1991; 14(4):319-30. PubMed ID: 1909615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population analysis of susceptibility to ciprofloxacin and nalidixic acid in Staphylococcus, Pseudomonas aeruginosa, and Enterobacteriaceae.
    Søgaard P; Gahrn-Hansen B
    Acta Pathol Microbiol Immunol Scand B; 1986 Oct; 94(5):351-6. PubMed ID: 3098043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gentamicin and amikacin---an in vitro comparison using 1000 clinical isolates.
    Forgan-Smith WR; McSweeney RJ
    Aust N Z J Med; 1978 Aug; 8(4):383-6. PubMed ID: 282852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.
    Wise R; Andrews JM; Brenwald N
    J Antimicrob Chemother; 1993 Jan; 31(1):73-80. PubMed ID: 8383104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.